Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Down 90.1% in April

Sunshine Biopharma, Inc. (NASDAQ:SBFM) was the recipient of a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 69,800 shares, a decrease of 90.1% from the March 31st total of 706,700 shares. Based on an average daily trading volume, of 881,000 shares, the short-interest ratio is presently 0.1 days. Approximately 7.3% of the company’s stock are short sold.

Sunshine Biopharma Trading Down 13.2 %

NASDAQ:SBFM traded down $0.12 during mid-day trading on Thursday, hitting $0.81. The stock had a trading volume of 13,931,183 shares, compared to its average volume of 897,672. Sunshine Biopharma has a twelve month low of $0.75 and a twelve month high of $140.00. The stock has a 50-day simple moving average of $6.13 and a two-hundred day simple moving average of $19.36. The company has a market capitalization of $799,326.00, a PE ratio of -0.04 and a beta of 1.17.

Sunshine Biopharma (NASDAQ:SBFM) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($5.00) earnings per share for the quarter. The firm had revenue of $7.68 million during the quarter. Sunshine Biopharma had a negative net margin of 18.70% and a negative return on equity of 21.03%.

Institutional Trading of Sunshine Biopharma

An institutional investor recently raised its position in Sunshine Biopharma stock. Armistice Capital LLC increased its holdings in shares of Sunshine Biopharma, Inc. (NASDAQ:SBFM) by 118.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,130,000 shares of the company’s stock after purchasing an additional 1,156,000 shares during the quarter. Armistice Capital LLC owned approximately 8.29% of Sunshine Biopharma worth $578,000 at the end of the most recent quarter. 41.98% of the stock is owned by institutional investors and hedge funds.

About Sunshine Biopharma

Sunshine Biopharma, Inc, a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; SBFM-PL4, an anti-coronavirus treatment compound; and K1.1 mRNA molecules used as anti-cancer agents.